Wolverine Trading
RVNC

Wolverine Trading’s Revance Therapeutics, Inc. RVNC Stock Holding History

Wolverine Trading’s Portfolio RVNC Stock Details RVNC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-13,931
Closed -$47.6K – 5367
2024
Q1 		$68.5K Buy
+13,931
New +$82.5K ﹤0.01% 4147
2023
Q3 		– Sell
-19,346
Closed -$372K – 5254
2023
Q2 		$478K Sell
19,346
-2,887
-13% -$89.9K ﹤0.01% 2647
2023
Q1 		$692K Buy
22,233
+8,386
+61% +$261K ﹤0.01% 2225
2022
Q4 		$256K Buy
13,847
+3,556
+35% +$81.3K ﹤0.01% 2922
2022
Q3 		$264K Buy
+10,291
New +$209K ﹤0.01% 3287
2019
Q4 		– Sell
-13,996
Closed -$217K – 5340
2019
Q3 		$193K Sell
13,996
-5,268
-27% -$64.5K ﹤0.01% 3613
2019
Q2 		$250K Buy
+19,264
New +$243K ﹤0.01% 3469
2019
Q1 		– Sell
-17,642
Closed -$306K – 5491
2018
Q4 		$342K Buy
17,642
+3,499
+25% +$77.1K ﹤0.01% 3052
2018
Q3 		$351K Buy
+14,143
New +$385K ﹤0.01% 3542
2018
Q1 		– Sell
-14,237
Closed -$458K – 5981
2017
Q4 		$509K Buy
+14,237
New +$409K ﹤0.01% 2977

Other funds holding RVNC

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Wolverine Trading's RVNC Position: Q2 2024 in Review

Wolverine Trading sold out of Revance Therapeutics, Inc. (RVNC) in Q2 2024, closing a stake of 13,931 shares — an estimated $47.6K sold.

Wolverine Trading first reported a position in RVNC in Q4 2017 and held it in 10 quarters. The position peaked at $692K in Q1 2023. 173 funds tracked by Wall St. Rank hold RVNC as of Q2 2024.

  • Wolverine Trading reported no remaining Revance Therapeutics, Inc. position as of Q2 2024 after selling out during the quarter.
  • Wolverine Trading sold 13,931 Revance Therapeutics, Inc. shares in Q2 2024, an estimated $47.6K.
  • Wolverine Trading first reported a position in Revance Therapeutics, Inc. in Q4 2017 and held it in 10 quarters.
  • Wolverine Trading's Revance Therapeutics, Inc. position peaked at $692K in Q1 2023.
  • 173 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q2 2024.

Based on Wolverine Trading's 13F filing for Q2 2024, filed 14 Aug 2024.